ACADIA PHARMACEUTICALS INC (ACAD)
US0042251084 - Common Stock
Overall ACAD gets a fundamental rating of 6 out of 10. We evaluated ACAD against 568 industry peers in the Biotechnology industry. ACAD is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ACAD is evaluated to be cheap and growing strongly. This does not happen too often! With these ratings, ACAD could be worth investigating further for value and growth investing!.
1. Profitability
1.1 Basic Checks
ACAD had positive earnings in the past year.
ACAD had a positive operating cash flow in the past year.
ACAD had negative earnings in each of the past 5 years.
ACAD had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 13.15%, ACAD belongs to the best of the industry, outperforming 97.52% of the companies in the same industry.
The Return On Equity of ACAD (22.26%) is better than 97.52% of its industry peers.
ACAD has a better Return On Invested Capital (14.01%) than 97.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.15% | ||
| ROE | 22.26% | ||
| ROIC | 14.01% |
ROA(3y)-22.97%
ROA(5y)-26.99%
ROE(3y)-33.06%
ROE(5y)-35.55%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of ACAD (13.83%) is better than 95.93% of its industry peers.
With an excellent Operating Margin value of 12.08%, ACAD belongs to the best of the industry, outperforming 95.40% of the companies in the same industry.
ACAD's Gross Margin of 91.61% is amongst the best of the industry. ACAD outperforms 93.63% of its industry peers.
In the last couple of years the Gross Margin of ACAD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.08% | ||
| PM (TTM) | 13.83% | ||
| GM | 91.61% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.38%
GM growth 5Y0.53%
2. Health
2.1 Basic Checks
ACAD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
ACAD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ACAD has more shares outstanding
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 2.69 indicates that ACAD is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of ACAD (2.69) is better than 73.98% of its industry peers.
There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 2.69 |
ROIC/WACC1.18
WACC11.91%
2.3 Liquidity
A Current Ratio of 2.29 indicates that ACAD has no problem at all paying its short term obligations.
ACAD's Current ratio of 2.29 is on the low side compared to the rest of the industry. ACAD is outperformed by 72.74% of its industry peers.
A Quick Ratio of 2.11 indicates that ACAD has no problem at all paying its short term obligations.
The Quick ratio of ACAD (2.11) is worse than 73.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.29 | ||
| Quick Ratio | 2.11 |
3. Growth
3.1 Past
ACAD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 184.78%, which is quite impressive.
The Revenue has grown by 47.05% in the past year. This is a very strong growth!
Measured over the past years, ACAD shows a very strong growth in Revenue. The Revenue has been growing by 26.55% on average per year.
EPS 1Y (TTM)184.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
Revenue 1Y (TTM)47.05%
Revenue growth 3Y18.03%
Revenue growth 5Y26.55%
Sales Q2Q%18.28%
3.2 Future
Based on estimates for the next years, ACAD will show a very strong growth in Earnings Per Share. The EPS will grow by 52.30% on average per year.
ACAD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.01% yearly.
EPS Next Y289.7%
EPS Next 2Y101.2%
EPS Next 3Y71.68%
EPS Next 5Y52.3%
Revenue Next Year36%
Revenue Next 2Y20.77%
Revenue Next 3Y17.27%
Revenue Next 5Y14.01%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 21.63 indicates a rather expensive valuation of ACAD.
Based on the Price/Earnings ratio, ACAD is valued cheaper than 95.04% of the companies in the same industry.
ACAD is valuated rather cheaply when we compare the Price/Earnings ratio to 27.73, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 21.67, which indicates a rather expensive current valuation of ACAD.
Based on the Price/Forward Earnings ratio, ACAD is valued cheaply inside the industry as 94.51% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.83, ACAD is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.63 | ||
| Fwd PE | 21.67 |
4.2 Price Multiples
96.46% of the companies in the same industry are more expensive than ACAD, based on the Enterprise Value to EBITDA ratio.
ACAD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ACAD is cheaper than 97.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.85 | ||
| EV/EBITDA | 14.52 |
4.3 Compensation for Growth
ACAD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of ACAD may justify a higher PE ratio.
ACAD's earnings are expected to grow with 71.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y101.2%
EPS Next 3Y71.68%
5. Dividend
5.1 Amount
No dividends for ACAD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ACADIA PHARMACEUTICALS INC
NASDAQ:ACAD (12/20/2024, 8:00:00 PM)
After market: 16.81 -0.06 (-0.36%)16.87
+0.14 (+0.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners94.45%
Inst Owner Change-2.77%
Ins Owners0.66%
Ins Owner Change6.55%
Market Cap2.81B
Analysts76.92
Price Target25.61 (51.81%)
Short Float %6.03%
Short Ratio7.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.9%
Min EPS beat(2)9.83%
Max EPS beat(2)41.97%
EPS beat(4)3
Avg EPS beat(4)37.91%
Min EPS beat(4)-9.66%
Max EPS beat(4)109.49%
EPS beat(8)5
Avg EPS beat(8)30.41%
EPS beat(12)8
Avg EPS beat(12)25.58%
EPS beat(16)12
Avg EPS beat(16)26.34%
Revenue beat(2)1
Avg Revenue beat(2)-0.34%
Min Revenue beat(2)-1.34%
Max Revenue beat(2)0.66%
Revenue beat(4)2
Avg Revenue beat(4)-0.64%
Min Revenue beat(4)-3.12%
Max Revenue beat(4)1.22%
Revenue beat(8)4
Avg Revenue beat(8)0.75%
Revenue beat(12)5
Avg Revenue beat(12)-1.07%
Revenue beat(16)6
Avg Revenue beat(16)-1.97%
PT rev (1m)-0.68%
PT rev (3m)-0.68%
EPS NQ rev (1m)128.77%
EPS NQ rev (3m)31.3%
EPS NY rev (1m)24.41%
EPS NY rev (3m)35.65%
Revenue NQ rev (1m)6.64%
Revenue NQ rev (3m)7.94%
Revenue NY rev (1m)1.14%
Revenue NY rev (3m)2.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.63 | ||
| Fwd PE | 21.67 | ||
| P/S | 3.02 | ||
| P/FCF | 13.85 | ||
| P/OCF | 13.85 | ||
| P/B | 4.86 | ||
| P/tB | 5.95 | ||
| EV/EBITDA | 14.52 |
EPS(TTM)0.78
EY4.62%
EPS(NY)0.78
Fwd EY4.61%
FCF(TTM)1.22
FCFY7.22%
OCF(TTM)1.22
OCFY7.22%
SpS5.58
BVpS3.47
TBVpS2.83
PEG (NY)0.07
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.15% | ||
| ROE | 22.26% | ||
| ROCE | 17.73% | ||
| ROIC | 14.01% | ||
| ROICexc | 131.18% | ||
| ROICexgc | N/A | ||
| OM | 12.08% | ||
| PM (TTM) | 13.83% | ||
| GM | 91.61% | ||
| FCFM | 21.81% |
ROA(3y)-22.97%
ROA(5y)-26.99%
ROE(3y)-33.06%
ROE(5y)-35.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.38%
GM growth 5Y0.53%
F-Score5
Asset Turnover0.95
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 0.57% | ||
| Cap/Sales | 0.01% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 162.79% | ||
| Profit Quality | 157.71% | ||
| Current Ratio | 2.29 | ||
| Quick Ratio | 2.11 | ||
| Altman-Z | 2.69 |
F-Score5
WACC11.91%
ROIC/WACC1.18
Cap/Depr(3y)251.6%
Cap/Depr(5y)210.75%
Cap/Sales(3y)1.91%
Cap/Sales(5y)1.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)184.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
EPS Next Y289.7%
EPS Next 2Y101.2%
EPS Next 3Y71.68%
EPS Next 5Y52.3%
Revenue 1Y (TTM)47.05%
Revenue growth 3Y18.03%
Revenue growth 5Y26.55%
Sales Q2Q%18.28%
Revenue Next Year36%
Revenue Next 2Y20.77%
Revenue Next 3Y17.27%
Revenue Next 5Y14.01%
EBIT growth 1Y172.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year292.07%
EBIT Next 3Y75.17%
EBIT Next 5Y71.62%
FCF growth 1Y278.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y278.93%
OCF growth 3YN/A
OCF growth 5YN/A